Bank of New York Mellon’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-413,279
| Closed | -$9.76M | – | 4358 |
|
|
2023
Q4 | $9.76M | Buy |
413,279
+37,730
| +10% | +$672K | ﹤0.01% | 2003 |
|
|
2023
Q3 | $5.6M | Sell |
375,549
-1,938
| -0.5% | -$25.7K | ﹤0.01% | 2258 |
|
|
2023
Q2 | $4.13M | Buy |
377,487
+337,506
| +844% | +$3.14M | ﹤0.01% | 2423 |
|
|
2023
Q1 | $349K | Buy |
39,981
+258
| +0.6% | +$2.06K | ﹤0.01% | 3680 |
|
|
2022
Q4 | $249K | Buy |
39,723
+10,942
| +38% | +$41.6K | ﹤0.01% | 3874 |
|
|
2022
Q3 | $101K | Sell |
28,781
-355
| -1% | -$1.27K | ﹤0.01% | 4195 |
|
|
2022
Q2 | $86K | Sell |
29,136
-247,630
| -89% | -$592K | ﹤0.01% | 4260 |
|
|
2022
Q1 | $861K | Buy |
276,766
+21,961
| +9% | +$69.1K | ﹤0.01% | 3406 |
|
|
2021
Q4 | $861K | Buy |
254,805
+5,009
| +2% | +$19K | ﹤0.01% | 3471 |
|
|
2021
Q3 | $911K | Buy |
249,796
+8,784
| +4% | +$34.6K | ﹤0.01% | 3442 |
|
|
2021
Q2 | $1.05M | Sell |
241,012
-35,408
| -13% | -$157K | ﹤0.01% | 3385 |
|
|
2021
Q1 | $1.25M | Sell |
276,420
-1,576
| -0.6% | -$8.48K | ﹤0.01% | 3212 |
|
|
2020
Q4 | $1.59M | Buy |
277,996
+31,366
| +13% | +$237K | ﹤0.01% | 2974 |
|
|
2020
Q3 | $1.79M | Sell |
246,630
-21,525
| -8% | -$115K | ﹤0.01% | 2737 |
|
|
2020
Q2 | $936K | Sell |
268,155
-14,982
| -5% | -$43.2K | ﹤0.01% | 3152 |
|
|
2020
Q1 | $419K | Buy |
283,137
+2,153
| +0.8% | +$3.62K | ﹤0.01% | 3461 |
|
|
2019
Q4 | $551K | Buy |
280,984
+16,303
| +6% | +$61.2K | ﹤0.01% | 3543 |
|
|
2019
Q3 | $1.35M | Sell |
264,681
-6,684
| -2% | -$40.5K | ﹤0.01% | 2987 |
|
|
2019
Q2 | $1.94M | Buy |
271,365
+13,193
| +5% | +$149K | ﹤0.01% | 2813 |
|
|
2019
Q1 | $3.43M | Buy |
258,172
+10,587
| +4% | +$113K | ﹤0.01% | 2513 |
|
|
2018
Q4 | $1.95M | Sell |
247,585
-11,726
| -5% | -$112K | ﹤0.01% | 2735 |
|
|
2018
Q3 | $2.87M | Buy |
259,311
+16,804
| +7% | +$209K | ﹤0.01% | 2662 |
|
|
2018
Q2 | $3.25M | Buy |
242,507
+114,001
| +89% | +$1.43M | ﹤0.01% | 2595 |
|
|
2018
Q1 | $1.67M | Sell |
128,506
-17,217
| -12% | -$214K | ﹤0.01% | 2913 |
|
|
2017
Q4 | $1.34M | Sell |
145,723
-9,451
| -6% | -$80.8K | ﹤0.01% | 3077 |
|
|
2017
Q3 | $1.25M | Buy |
155,174
+137,830
| +795% | +$932K | ﹤0.01% | 3109 |
|
|
2017
Q2 | $100K | Buy |
17,344
+140
| +0.8% | +$596 | ﹤0.01% | 4026 |
|
|
2017
Q1 | $74K | Hold |
17,204
| – | – | ﹤0.01% | 4084 |
|
|
2016
Q4 | $30K | Sell |
17,204
-1,079
| -6% | -$1.91K | ﹤0.01% | 4181 |
|
|
2016
Q3 | $35K | Sell |
18,283
-3,596
| -16% | -$7.15K | ﹤0.01% | 4176 |
|
|
2016
Q2 | $38K | Buy |
21,879
+500
| +2% | +$1.04K | ﹤0.01% | 4222 |
|
|
2016
Q1 | $29K | Sell |
21,379
-768
| -3% | -$951 | ﹤0.01% | 4146 |
|
|
2015
Q4 | $37K | Sell |
22,147
-7,728
| -26% | -$12.6K | ﹤0.01% | 4221 |
|
|
2015
Q3 | $58K | Buy |
+29,875
| New | +$81.3K | ﹤0.01% | 4228 |
|
Other funds holding CBAY
Bank of New York Mellon's CBAY Position: Q1 2024 in Review
Bank of New York Mellon sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 413,279 shares — an estimated $9.76M sold.
Bank of New York Mellon first reported a position in CBAY in Q3 2015 and held it in 34 quarters. The position peaked at $9.76M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Bank of New York Mellon reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Bank of New York Mellon sold 413,279 Cymabay Therapeutics shares in Q1 2024, an estimated $9.76M.
- Bank of New York Mellon first reported a position in Cymabay Therapeutics in Q3 2015 and held it in 34 quarters.
- Bank of New York Mellon's Cymabay Therapeutics position peaked at $9.76M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Bank of New York Mellon's 13F filing for Q1 2024, filed 25 Apr 2024.